查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1597834

T 细胞治疗市场：依方式、治疗类型、适应症分类 - 全球预测 2025-2030

T-Cell Therapy Market by Modality (Commercialized, Research), Therapy Type (CAR T-cell Therapy, T Cell Receptor-Based, Tumor Infiltrating Lymphocytes-Based), Indication - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年T细胞治疗市值为81.3亿美元，预计2024年将达到98.5亿美元，复合年增长率为21.23%，到2030年将达到313亿美元。

T细胞疗法是免疫疗法的一个重要方面，利用基因工程T细胞来靶向并摧毁癌细胞，在现代癌症治疗中显示出巨大的潜力。需求在于能够解决对传统治疗没有反应的肿瘤并描述个人化治疗方案。其应用和最终用途范围从白血病和淋巴瘤等血癌到固体癌，包括医院、研究机构和生物技术公司。推动市场成长的关键因素是CAR-T和TCR疗法的进步、生物技术投资的增加以及癌症发生率的上升。然而，生产成本、复杂的监管环境和潜在的副作用是阻碍成长的显着限制。最新的机会来自于 CRISPR 等基因编辑技术的进步，这些技术提高了 T 细胞的有效性，并将其扩展到自体免疫疾病等非肿瘤应用领域。为了利用这些机会，鼓励生物技术公司和学术机构合作以简化製造流程并降低成本。此外，可以透过专注于改善新型载体系统和递送方法的安全性来解决监管挑战和社会问题。儘管有这项承诺，市场仍面临一些障碍，例如治疗成本高、冷冻细胞运输的物流以及需要大规模临床测试以确保安全性和有效性。创新可能会在同种异体 T 细胞的开发等领域蓬勃发展，这可以减少製造时间和成本，以及使用次世代定序方法来提高目标识别的准确性并确保精准医疗。此外，人工智慧还可用于患者选择和治疗方法定制，以实现优化的治疗结果。随着技术的快速进步，市场动态也高度动态，因此相关人员在不断发展的研发领域保持敏捷以保持竞争力至关重要。

主要市场统计
基准年[2023] 81.3亿美元
预测年份 [2024] 98.5亿美元
预测年份 [2030] 313亿美元
复合年增长率（%） 21.23%

市场动态：揭示快速发展的 T 细胞治疗市场的关键市场洞察

T 细胞治疗市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 随着製造能力的扩大，核准增加
    • 癌症盛行率成长速度惊人
    • 获得政府认可的适当报销
  • 市场限制因素
    • CAR T 细胞免疫疗法疗效的限制以及 CAR T 细胞归巢至肿瘤沉积物的不足
  • 市场机会
    • 免疫肿瘤学领域研发支出快速成长
    • 扩大基因和细胞疗法的采用
  • 市场问题
    • 安全性问题和可能的副作用

波特五力：驾驭 T 细胞治疗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解 T 细胞治疗市场的外部影响

外部宏观环境因素在塑造 T 细胞治疗市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解T细胞治疗市场的竞争格局

T 细胞治疗市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的见解，以应对日益激烈的竞争。

FPNV 定位矩阵：T 细胞治疗市场供应商的绩效评估

FPNV定位矩阵是评估T细胞治疗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製 T 细胞治疗市场的成功之路

T 细胞治疗市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1.市场渗透率：对当前市场环境的详细审查，主要企业的广泛资料，评估他们在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 随着製造能力的扩大，核准增加
      • 癌症发生率成长速度惊人
      • 根据政府认可提供适当补偿
    • 抑制因素
      • CAR-T细胞免疫疗法疗效的限制以及CAR-T细胞对肿瘤沉积物的归巢不足
    • 机会
      • 免疫肿瘤学领域的研发经费快速增加
      • 扩大基因/细胞疗法的引入
    • 任务
      • 安全性问题和可能的副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章 T 细胞治疗市场：依方式分类

  • 介绍
  • 商业化
  • 研究

第七章 T 细胞治疗市场：依治疗类型

  • 介绍
  • CAR-T细胞疗法
  • 基于T细胞受体
  • 基于肿瘤浸润淋巴细胞

第八章 T 细胞治疗市场：依适应症分类

  • 介绍
  • 造血系统恶性
    • 白血病
    • 淋巴瘤
    • 骨髓瘤
  • 固态肿瘤
    • 大脑和中枢神经系统
    • 肝癌
    • 恶性黑色素瘤

第九章 美洲T细胞治疗市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太T细胞治疗市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲T细胞治疗市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Adaptimmune Therapeutics PLC
  • Amgen Inc.
  • Bluebird Bio, Inc.
  • Bristol Myers Squibb
  • DiaCarta, Inc.
  • Fate Therapeutics Inc.
  • Gilead Sciences, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Poseida Therapeutics Inc.
  • Sorrento Therapeutics, Inc.
  • Takara Bio Inc.
  • Tessa Therapeutics Pte. Ltd.
Product Code: MRR-A26E0E5744D4

The T-Cell Therapy Market was valued at USD 8.13 billion in 2023, expected to reach USD 9.85 billion in 2024, and is projected to grow at a CAGR of 21.23%, to USD 31.30 billion by 2030.

T-cell therapy, a pivotal facet of immunotherapy, utilizes genetically modified T-cells to target and destroy cancer cells, presenting significant potential in modern oncology treatments. Its necessity lies in its ability to address tumors unresponsive to conventional therapies, offering personalized treatment options. The application and end-use scope range from blood cancers, such as leukemia and lymphoma, to solid tumors, spanning hospitals, research institutes, and biotech companies. Market growth is predominantly driven by advancements in CAR-T and TCR therapies, increased investment in biotechnology, and rising cancer prevalence. However, production cost, complex regulatory landscapes, and potential side effects serve as notable limitations hindering growth. The latest opportunities arise from advances in gene editing technologies like CRISPR, which could enhance T-cell efficacy, and expansion into non-oncological applications, such as autoimmune diseases. To capitalize on these opportunities, collaboration between biotech firms and academic institutions to streamline manufacturing processes and mitigate costs is recommended. Moreover, focusing on improving safety profiles through novel vector systems and delivery methods can address regulatory challenges and public concerns. Despite these prospects, the market faces hurdles in terms of high therapy costs, logistics of cryopreserved cell transport, and the need for extensive clinical trials to ensure safety and efficacy. Innovation can thrive in areas like developing allogeneic T-cells, which could reduce manufacturing time and cost, and harnessing next-generation sequencing methods for better target identification, ensuring precision medicine. Additionally, tapping into artificial intelligence for patient selection and therapy customization can yield optimized outcomes. The nature of the market is highly dynamic, with rapid technological progress, making it crucial for stakeholders to remain agile and responsive to evolving research and development fronts to maintain a competitive edge.

KEY MARKET STATISTICS
Base Year [2023] USD 8.13 billion
Estimated Year [2024] USD 9.85 billion
Forecast Year [2030] USD 31.30 billion
CAGR (%) 21.23%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving T-Cell Therapy Market

The T-Cell Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing approvals along with expanding manufacturing capabilities
    • Alarming rate of increase in prevalence of cancers
    • Availability of adequate reimbursements with government awareness
  • Market Restraints
    • Limitations of efficacy of CAR T-cell immunotherapy and inadequate homing of CAR T-cells to tumor deposits
  • Market Opportunities
    • Exponential R&D funding for immuno-oncology sector
    • Expanding adoption of gene and cell therapy
  • Market Challenges
    • Safety issues and possible side-effects

Porter's Five Forces: A Strategic Tool for Navigating the T-Cell Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the T-Cell Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the T-Cell Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the T-Cell Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the T-Cell Therapy Market

A detailed market share analysis in the T-Cell Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the T-Cell Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the T-Cell Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the T-Cell Therapy Market

A strategic analysis of the T-Cell Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the T-Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adaptimmune Therapeutics PLC, Amgen Inc., Bluebird Bio, Inc., Bristol Myers Squibb, DiaCarta, Inc., Fate Therapeutics Inc., Gilead Sciences, Inc., Merck KGaA, Novartis AG, Pfizer Inc., Poseida Therapeutics Inc., Sorrento Therapeutics, Inc., Takara Bio Inc., and Tessa Therapeutics Pte. Ltd..

Market Segmentation & Coverage

This research report categorizes the T-Cell Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Modality, market is studied across Commercialized and Research.
  • Based on Therapy Type, market is studied across CAR T-cell Therapy, T Cell Receptor-Based, and Tumor Infiltrating Lymphocytes-Based.
  • Based on Indication, market is studied across Hematologic Malignancies and Solid Tumors. The Hematologic Malignancies is further studied across Leukemia, Lymphoma, and Myeloma. The Solid Tumors is further studied across Brain & Central Nervous System, Liver Cancer, and Melanoma.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing approvals along with expanding manufacturing capabilities
      • 5.1.1.2. Alarming rate of increase in prevalence of cancers
      • 5.1.1.3. Availability of adequate reimbursements with government awareness
    • 5.1.2. Restraints
      • 5.1.2.1. Limitations of efficacy of CAR T-cell immunotherapy and inadequate homing of CAR T-cells to tumor deposits
    • 5.1.3. Opportunities
      • 5.1.3.1. Exponential R&D funding for immuno-oncology sector
      • 5.1.3.2. Expanding adoption of gene and cell therapy
    • 5.1.4. Challenges
      • 5.1.4.1. Safety issues and possible side-effects
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. T-Cell Therapy Market, by Modality

  • 6.1. Introduction
  • 6.2. Commercialized
  • 6.3. Research

7. T-Cell Therapy Market, by Therapy Type

  • 7.1. Introduction
  • 7.2. CAR T-cell Therapy
  • 7.3. T Cell Receptor-Based
  • 7.4. Tumor Infiltrating Lymphocytes-Based

8. T-Cell Therapy Market, by Indication

  • 8.1. Introduction
  • 8.2. Hematologic Malignancies
    • 8.2.1. Leukemia
    • 8.2.2. Lymphoma
    • 8.2.3. Myeloma
  • 8.3. Solid Tumors
    • 8.3.1. Brain & Central Nervous System
    • 8.3.2. Liver Cancer
    • 8.3.3. Melanoma

9. Americas T-Cell Therapy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific T-Cell Therapy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa T-Cell Therapy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Adaptimmune Therapeutics PLC
  • 3. Amgen Inc.
  • 4. Bluebird Bio, Inc.
  • 5. Bristol Myers Squibb
  • 6. DiaCarta, Inc.
  • 7. Fate Therapeutics Inc.
  • 8. Gilead Sciences, Inc.
  • 9. Merck KGaA
  • 10. Novartis AG
  • 11. Pfizer Inc.
  • 12. Poseida Therapeutics Inc.
  • 13. Sorrento Therapeutics, Inc.
  • 14. Takara Bio Inc.
  • 15. Tessa Therapeutics Pte. Ltd.

LIST OF FIGURES

  • FIGURE 1. T-CELL THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. T-CELL THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL T-CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL T-CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL T-CELL THERAPY MARKET SIZE, BY MODALITY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL T-CELL THERAPY MARKET SIZE, BY MODALITY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES T-CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES T-CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. T-CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. T-CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. T-CELL THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL T-CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL T-CELL THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. T-CELL THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL T-CELL THERAPY MARKET SIZE, BY COMMERCIALIZED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL T-CELL THERAPY MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL T-CELL THERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL T-CELL THERAPY MARKET SIZE, BY T CELL RECEPTOR-BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL T-CELL THERAPY MARKET SIZE, BY TUMOR INFILTRATING LYMPHOCYTES-BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL T-CELL THERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL T-CELL THERAPY MARKET SIZE, BY MYELOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL T-CELL THERAPY MARKET SIZE, BY BRAIN & CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL T-CELL THERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL T-CELL THERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES T-CELL THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 234. T-CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 235. T-CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023